



## Erectile Dysfunction in Men with Diabetes: Pathophysiology and Treatment Approaches

\*<sup>1</sup>UBHENIN, AE; <sup>1</sup>ANURA, F; <sup>1</sup>IDRIS, RI; <sup>2</sup>INNIH, SO

<sup>1</sup>Department of Biochemistry, Faculty of Sciences, Federal University Lafia, Nasarawa State, Nigeria

<sup>2</sup>Department of Anatomy, Faculty of Medicine, University of Benin, PMB 1154, Benin City, Nigeria

\*Corresponding Author Email: [ehibram@yahoo.co.uk](mailto:ehibram@yahoo.co.uk)

\*Tel: +2348133893080

Co-Author Email: [anura4teemah@gmail.com](mailto:anura4teemah@gmail.com); [iyayana67@gmail.com](mailto:iyayana67@gmail.com); [silvanus.innih@uniben.edu](mailto:silvanus.innih@uniben.edu)

**ABSTRACT:** Erectile dysfunction (ED) is a prevalent condition with significant physiological and psychological implications for men, particularly those with diabetes. Therefore, this paper aims to conduct a systematic review to explore the multifaceted aspects of ED in men with diabetes, encompassing prevalence, risk factors, pathophysiology, diagnostic methods, treatments, psychological interventions, and emerging therapies. Secondary data were gathered through a comprehensive literature search of reputable databases using relevant keywords from 1996 to 2020. The data obtained indicate that the global prevalence of ED increases with age, with substantial rates observed in older men. Cardiovascular risk factors, diabetes, hormonal imbalances, and psychological factors are identified as major contributors to ED development. The quality of life of men with ED is profoundly affected, leading to psychological distress and strained relationships. Future perspectives involve personalized treatments, nanotechnology, and innovative therapies. While promising, challenges in managing ED include stigma, underreporting, complex etiology, and limited access to specialized care. Comprehensive and individualized approaches are crucial to optimize treatment outcomes for men with ED, particularly those with diabetes.

DOI: <https://dx.doi.org/10.4314/jasem.v28i6.10>

**Open Access Policy:** All articles published by **JASEM** are open-access articles and are free for anyone to download, copy, redistribute, repost, translate and read.

**Copyright Policy:** © 2024. Authors retain the copyright and grant **JASEM** the right of first publication with the work simultaneously licensed under the **Creative Commons Attribution 4.0 International (CC-BY-4.0) License**. Any part of the article may be reused without permission provided that the original article is cited.

**Cite this Article as:** UBHENIN, A. E; ANURA, F; IDRIS, R. I; INNIH, S. O (2024). Erectile Dysfunction in Men with Diabetes: Pathophysiology and Treatment Approaches. *J. Appl. Sci. Environ. Manage.* 28 (6) 1719-1727

**Dates:** Received: 21 February 2024; Revised: 22 March 2024; Accepted: 20 April 2024 Published: 06 June 2024

**Keywords:** Erectile dysfunction; Diabetes; Prevalence; Pathophysiology; Emerging therapies

Erectile dysfunction (ED) is a prevalent condition that affects men's sexual health and overall well-being (Hatzimouratidis *et al.*, 2007). It is characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance (Nguyen *et al.*, 2017). ED is a multifactorial condition influenced by physiological, psychological, and lifestyle factors. The global prevalence of ED varies depending on age, with rates ranging from 2% to 9% in younger men and increasing significantly to 70% to 90% in men over 70 years old (Ryu, *et al.*, 2013). Chronic medical conditions, such as diabetes, hypertension, cardiovascular disease, and neurological

disorders, contribute to the development of ED (Somers *et al.*, 2008). Among men with diabetes, the prevalence of ED is particularly high due to the adverse effects of hyperglycemia on blood vessels and nerves. However, specific data on the prevalence of ED in Nigeria is limited, but studies suggest a high prevalence of sexual dysfunction among Nigerian men, especially those with diabetes. Understanding the prevalence of ED is crucial for raising awareness and implementing appropriate interventions to address this significant public health concern. Therefore, the aim of this paper was to conduct a systematic review to thoroughly investigate the multifaceted aspects of

\*Corresponding Author Email: [ehibram@yahoo.co.uk](mailto:ehibram@yahoo.co.uk)

\*Tel: +2348133893080

erectile dysfunction (ED) in men with diabetes. This comprehensive exploration encompasses the examination of prevalence rates, identification of risk factors, elucidation of pathophysiological mechanisms, evaluation of diagnostic methodologies, assessment of available treatments, consideration of psychological interventions, and exploration of emerging therapies. To achieve this aim, secondary data and information were collected through a rigorous literature search utilizing reputable databases and pertinent keywords spanning the period from 1996 to 2020.

## MATERIALS AND METHODS

The methodology for the review on erectile dysfunction (ED) in men with diabetes involves a systematic harvesting secondary data and information from literature search using reputable databases and relevant keywords from 1996-2020. Inclusion criteria were defined to select peer-reviewed studies focusing on ED in diabetic men, while animal studies and insufficient data were excluded. Two independent reviewers were screened and selected eligible studies, and data was extracted using a standardized form, covering study characteristics, participant information, ED prevalence, risk factors, pathophysiology, diagnostic methods, treatments, psychological interventions, and emerging therapies. Data was synthesized and analyzed descriptively, with potential meta-analysis if feasible. The quality of selected studies was assessed, and limitations and biases were discussed. The review aims to provide an evidence-based overview of ED in men with diabetes and offer recommendations for future research and clinical practice. Overall, this systematic review comprehensively investigated the prevalence, risk factors, pathophysiology, diagnostic methods, treatments, psychological interventions, and emerging therapies for erectile dysfunction in men with diabetes. By rigorously searching and selecting relevant studies, assessing quality, and conducting data synthesis, the review aims to offer valuable insights into the complex condition and provide evidence-based recommendations for clinicians and researchers.

*Erectile Dysfunction (ED) Prevalence Increases with Age:* Research consistently shows that erectile dysfunction (ED) prevalence increases with age. In younger men, ED is relatively uncommon, with rates ranging from 2% to 9% in those under 40 years old. However, the prevalence starts rising notably in middle-aged men, with rates ranging from 20% to 40% in men aged 40 to 49 (Laumann *et al.*, 2008). In men aged 50 to 59, the prevalence further increases to about 30% to 50%, and in their 60s and 70s, approximately 50% to 70% of men experience ED (McCabe *et*

*al.*, 2016). Among men over 70, ED is highly prevalent, with rates ranging from 70% to 90% (Rhoden, *et al.*, 2002). The age-related increase in ED is attributed to various physiological and psychological factors. Aging leads to changes in the vascular system, resulting in reduced blood flow and impaired endothelial function, hindering the ability to achieve and maintain erections (Bivalacqua *et al.*, 2003). Gradual declines in testosterone levels, which play a role in sexual desire and erectile function, also contribute to the increased prevalence of ED in older men. Age-related comorbidities like diabetes, cardiovascular disease, and hypertension become more common as men age and are strongly associated with ED (Jackson *et al.*, 2006). Psychological factors, such as increased stress, anxiety, and concerns about sexual performance, may also contribute to the age-related rise in ED prevalence (Solomon *et al.*, 2003). Age-related changes in the nervous system and neural pathways involved in penile erection can impact erectile function, leading to difficulties in achieving and maintaining erections. Additionally, the decline in penile sensitivity and smooth muscle function in older men can also contribute to the development of ED (Leung, *et al.*, 2004). It is essential to recognize that age alone is not the sole determinant of sexual function. Many older men can still enjoy satisfactory sexual activity and function well in their later years. Early detection and management of ED in older men are crucial to improving their quality of life, overall health, and sexual well-being. Timely interventions can address underlying causes and potentially prevent further progression of the condition. Raising awareness of this age-related trend can aid health care professionals in offering appropriate counseling, interventions, and treatments to improve the sexual health and well-being of aging male populations.

*The Risk Factors and Comorbidities Associated with Erectile Dysfunction (ED):* Research has consistently shown that erectile dysfunction (ED) is associated with various risk factors and comorbidities. Cardiovascular risk factors, such as hypertension, dyslipidemia, obesity, and metabolic syndrome, contribute to ED by affecting blood vessel health and reducing penile blood flow. Diabetes mellitus is another well-established risk factor for ED, as chronic high blood glucose levels can damage nerves and blood vessels essential for erections (Müller and Mulhall, 2006). Smoking and excessive alcohol consumption have been linked to ED due to their negative impact on blood vessel function and hormonal imbalances. Psychological factors, including stress, anxiety, and depression, disrupt normal physiological responses involved in achieving

erections, leading to ED (Nguyen, *et al.*, 2017). Age itself is a risk factor for ED, as men experience age-related physiological changes, such as reduced testosterone levels and increased vascular stiffness, which can contribute to erectile difficulties (Camacho *et al.*, 2005). Hormonal imbalances, particularly low testosterone levels, also play a role in decreased sexual desire and erectile problems (Corona *et al.*, 2004). Neurological conditions like multiple sclerosis, Parkinson's disease, and spinal cord injuries can damage the nerves responsible for erections, leading to ED (Nehra and Moreland, 2001). Pelvic surgeries or trauma can cause nerve or blood vessel damage, and certain medications, including antihypertensives, antidepressants, and antipsychotics, have been associated with an increased risk of ED as a side effect (Wyllie, 2005). Men with pre-existing cardiovascular diseases, such as coronary artery disease, are more susceptible to ED due to compromised blood flow and endothelial dysfunction. Peyronie's disease, characterized by fibrous plaques in the penis, can cause penile curvature and contribute to ED. Understanding these risk factors and comorbidities is vital for identifying men at risk of developing ED and tailoring effective prevention and treatment strategies. Addressing underlying health issues can lead to improved sexual health and overall well-being for men affected by ED.

*The Pathophysiology of Erectile Dysfunction (ED):* Erectile dysfunction (ED) is a common condition that significantly impacts the quality of life for affected individuals. Extensive research findings have shed light on the complex pathophysiology of ED, involving various physiological and neural factors. Vascular pathways play a central role in penile erections, with nitric oxide (NO) being a key mediator (Tuteja, *et al.*, 2004). Reduced NO bioavailability and endothelial dysfunction lead to inadequate vasodilation of penile blood vessels, resulting in reduced blood flow and ED (Toda, 2012). The cyclic guanosine monophosphate (cGMP) pathway is crucial for smooth muscle relaxation in the penile corpus cavernosum during erections, and its dysregulation contributes to ED (Andersson, 2003).

Neurological factors are also integral to erectile function, with complex neural pathways involving parasympathetic, sympathetic, sensory, and motor nerves. Central neural pathways originating from the brain signal the release of neurotransmitters that regulate penile smooth muscle relaxation and blood flow. Neurological disorders, such as multiple sclerosis and spinal cord injuries, can damage the nerves involved in penile erection, leading to ED (Nehra and Moreland, impacting erectile function

(Dwyer and Quinton, 2019). Penile smooth muscle and connective tissue play a critical role in penile erections. Relaxation of penile smooth muscle allows for increased blood flow, while changes in smooth muscle and connective tissue composition, like fibrosis and collagen deposition, can reduce elasticity and compliance, contributing to ED (El-Sakka and Yassin, 2010). Cardiovascular factors significantly impact ED, with atherosclerosis, hypertension, and dyslipidemia playing prominent roles. Atherosclerosis can impede blood flow to the penile arteries, while hypertension affects blood vessel health and reduces penile blood flow. Dyslipidemia can lead to atherosclerosis, further contributing to ED (Kloner and Speakman, 2002).

Drug-induced ED is a recognized issue, with certain medications, such as antidepressants and antihypertensives, causing ED as side effects due to their effects on neural and vascular pathways (Valeiro *et al.* 2022).

*The Genetic Aspects of Erectile Dysfunction (ED):* Research into the genetic aspects of Erectile Dysfunction (ED) has investigated various factors that may contribute to its development. Studies have explored genetic variations in key genes, such as endothelial nitric oxide synthase (eNOS), which affects nitric oxide production and vascular function, and phosphodiesterase type 5 (PDE5), involved in regulating cyclic guanosine monophosphate (cGMP) for penile erection (Bivalacqua *et al.* 2007). Genetic variants in the androgen receptor (AR) gene, impacting androgen signaling, have also been studied for their potential role in ED risk. Genome-wide association studies (GWAS) have identified potential candidate genes and genomic regions associated with ED susceptibility (Talas *et al.* 2016). Candidate gene studies have focused on pathways like neurotransmitter signaling, hormone regulation, and vascular function (Baskerville and Douglas, 2010). While these findings underscore a genetic component, ED remains influenced by complex interactions between genetics, environment, lifestyle, and psychological factors. Further research is needed to comprehensively unravel the genetic mechanisms contributing to ED and their interplay with other determinants. Understanding the complex pathophysiology of ED is essential for developing effective treatments and interventions. Targeting specific pathways involved in ED may offer new therapeutic strategies to improve sexual health and overall well-being in those affected by this condition.

*The Diagnostic Methods for Erectile Dysfunction (ED):* An accurate diagnosis of erectile dysfunction

(ED) is essential for effective management and treatment. To achieve this, various diagnostic methods have been extensively researched and established. Medical history and patient questionnaires play a fundamental role in identifying ED. Detailed questions about sexual function, medical conditions, medications, lifestyle factors, and psychological aspects are essential for understanding the patient's overall health and potential contributors to ED. The International Index of Erectile Function (IIEF) questionnaire is a widely used tool to assess ED severity and its impact on the patient's quality of life, aiding in diagnosis and treatment planning (Grover and Shouan, 2020).

Physical examination is a crucial component of the diagnostic process. It helps identify potential physical causes of ED, such as vascular problems, neurological abnormalities, or hormonal imbalances. Assessing blood pressure, performing a genital examination, and evaluating secondary sexual characteristics provide valuable insights into the patient's overall health and possible contributing factors to ED. Laboratory tests are vital for diagnosing ED. Blood tests can measure hormone levels, including testosterone, prolactin, and thyroid function, to identify hormonal imbalances that may be impacting erectile function (Mechanick, 2003). Fasting blood glucose and lipid profiles help diagnose diabetes and dyslipidemia, both of which are significant risk factors for ED. Psychological evaluation and assessment are crucial in diagnosing ED, as psychological factors can contribute to the condition. Through questionnaires or interviews, healthcare professionals can identify anxiety, depression, or other mental health issues that may be affecting sexual function. Objective assessments of erectile function during sleep are valuable diagnostic tools. Nocturnal Penile Tumescence (NPT) testing measures spontaneous erections during REM sleep, providing insights into erectile health. Men with healthy erectile function typically experience multiple erections during sleep, while those with ED may have fewer or no nocturnal erections. Advanced imaging techniques such as Penile Doppler ultrasound and Magnetic Resonance Angiography (MRA) help assess penile blood flow and identify vascular causes of ED, such as arterial insufficiency or venous leakage (Ma *et al.*, 2020).

Intracavernosal Injection (ICI) tests involve the injection of vasoactive medications to induce erections, aiding in determining physiological issues with penile blood flow (Belew *et al.*, 2015). Dynamic Infusion Caverosometry and cavernosography (DICC) involves injecting contrast dye to visualize blood flow and assess the penile vascular system,

useful in cases where vascular abnormalities are suspected (Chen *et al.*, 1996).

Hormone stimulation tests, such as the gonadotropin-releasing hormone (GnRH) test and the nocturnal penile tumescence and rigidity (NPTR) test, help identify hormonal deficiencies contributing to ED. Penile Nerve Conduction Studies assess the function of the nerves responsible for penile sensation and erection, useful in diagnosing nerve-related causes of ED, such as neuropathies or nerve injuries. Rigiscan testing objectively measures changes in penile rigidity during sleep, providing valuable data on the quality and duration of nighttime erections.

*Treatment for Erectile Dysfunction (ED):* Research findings have identified a range of effective treatment options for erectile dysfunction (ED). Oral phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, tadalafil, and vardenafil, are considered the first-line treatment for ED (Wright, 2006). Extensive research has demonstrated that these medications enhance the effects of nitric oxide on penile smooth muscle, leading to increased blood flow and sustained erections (Wright, 2006). PDE5 inhibitors have shown high response rates and are generally safe and effective for men with various underlying causes of ED. Intracavernosal injections (ICI) involve directly injecting vasoactive medications, such as alprostadil, into the penile shaft to induce an erection (Davies, 2015). Research findings indicate that ICI is a viable treatment option for men who do not respond to or cannot tolerate oral medications. These injections are well-tolerated and can produce reliable erections within minutes. Vacuum erection devices (VEDs) are non-invasive devices that create a vacuum around the penis, drawing blood into the penile tissues to facilitate an erection (Krzastek *et al.*, 2019). Studies have shown that VEDs are safe and effective for men with ED, including those with diabetes or who have undergone prostate surgery. Intraurethral suppositories, specifically alprostadil, can be administered directly into the urethra to promote penile blood flow and induce erections (Montorsi *et al.*, 2003). Research has demonstrated the effectiveness of intraurethral suppositories (MUSE) in producing erections, making it an alternative treatment option for men unable to use other therapies. For severe and refractory cases of ED, penile implants, including inflatable and semi-rigid devices, are surgically implanted into the penis to provide on-demand erections. Research findings indicate high patient satisfaction rates with penile implants, making them a valuable option for certain individuals. Testosterone replacement therapy (TRT) is effective for men with low testosterone levels contributing to ED. Research has shown that TRT can



improve sexual function and erectile quality in men with testosterone deficiency. Lifestyle changes, such as weight loss, regular exercise, and smoking cessation, can also improve erectile function for some men. Additionally, counseling or sex therapy can be beneficial for men with ED related to psychological factors, helping them address performance anxiety and relationship issues. Researchers are actively investigating novel therapies for ED, including stem cell therapy, shockwave therapy, and gene therapy. Preliminary findings show promise, but further research is needed to establish their safety and long-term efficacy (Jiang *et al.*, 2021).

*The Psychological Interventions for Erectile Dysfunction (ED):* Extensive research findings have highlighted several effective psychological interventions for erectile dysfunction (ED). Cognitive-Behavioral Therapy (CBT) has shown to be a widely studied and effective approach, helping men modify negative thought patterns and beliefs related to sexual performance and self-esteem (Avagianou, 2014). By reducing anxiety and performance-related concerns, CBT leads to improved sexual confidence and erectile function. Sex therapy, involving counseling sessions with specialized therapists, addresses emotional and relationship factors contributing to ED. Couples counseling is often incorporated to improve communication and intimacy, leading to enhanced sexual satisfaction. Sensate focus exercises, a form of behavioral therapy used in sex therapy, have demonstrated their effectiveness in increasing intimacy and reducing performance pressure during sexual activities, resulting in improved sexual function (Rosen, 2001). Mindfulness-based interventions like mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) have shown promise in enhancing sexual functioning by reducing sexual performance anxiety and increasing overall sexual satisfaction. Hypnotherapy has been explored as a potential treatment for ED, with some findings suggesting its positive impact on addressing psychological factors contributing to ED and improving sexual function. Couple therapy has proven beneficial when ED affects relationship dynamics. Addressing relationship issues and communication problems through couple's therapy has been shown to improve sexual functioning and overall relationship satisfaction. Education and informational interventions that provide knowledge about ED, its causes, and available treatments have been found to reduce anxiety and improve treatment adherence in some men. Acceptance and Commitment Therapy (ACT), a form of therapy that focuses on accepting difficult thoughts and feelings and committing to positive behavioral changes, has shown potential in

reducing sexual performance anxiety and improving sexual functioning. Internet-based interventions, such as online cognitive-behavioral therapy or self-help programs, offer accessibility and convenience for patients seeking psychological support for ED and have demonstrated effectiveness in improving sexual function.

*The Emerging Therapies and Future Directions for Erectile Dysfunction (ED):* The emerging therapies and future directions for treating erectile dysfunction (ED) show promising and diverse possibilities. Gene therapy, which involves modifying target cells through genetic material delivery, has demonstrated encouraging results in animal models and is being explored to enhance nitric oxide production or other molecules involved in erectile function. Stem cell therapy shows potential in regenerating damaged tissues and improving penile blood flow, making it a promising avenue for treating ED caused by vascular or nerve damages (Gur *et al.*, 2018). Extracorporeal shockwave therapy (ESWT), a non-invasive treatment using shockwaves to stimulate tissue repair and blood flow, has shown beneficial effects on erectile function by promoting neovascularization and tissue regeneration. Low-intensity electromagnetic stimulation (Li-ESWT) is another non-invasive approach that has demonstrated improvements in erectile function and penile blood flow in men with ED (Lin *et al.*, 2017). Researchers are investigating the use of phosphodiesterase type 5 (PDE5) inhibitor nanoparticles for targeted and sustained drug delivery to the penis. This method aims to enhance the effectiveness of PDE5 inhibitors while reducing systemic side effects. Novel androgen receptor modulators are being developed to selectively target penile tissues, aiming to improve erectile function without adverse effects on other organs (Zhang and Sui, 2013). Melanocortin receptor agonists are being studied for their potential to improve erectile function by acting on the central nervous system. These agents may offer an alternative treatment for ED, particularly in cases where PDE5 inhibitors are ineffective or unsuitable. Combination therapies, such as combining PDE5 inhibitors with other medications or therapies, are being explored to target multiple aspects of ED's pathophysiology for better outcomes. Telemedicine and digital health platforms present convenient and accessible ways to provide psychological support and education for men with ED, potentially improving treatment adherence and patient engagement. The future direction in ED treatment involves a shift toward precision medicine, where individual patient characteristics and genetic profiles are considered to tailor specific treatments. Personalized treatments may offer improved outcomes and reduced side effects,

reflecting a more targeted and individualized approach to managing ED.

*The Quality of Life and Psychological Impact of Erectile Dysfunction (ED):* Extensive research findings reveal that erectile dysfunction (ED) has a considerable negative impact on the quality of life for affected men. Studies consistently demonstrate that ED leads to reduced sexual satisfaction, intimacy, and overall relationship satisfaction (Byers, 2005). Beyond sexual function, men with ED experience feelings of frustration, embarrassment, and low self-esteem. Psychological distress, including anxiety and depression, is common among men with ED, and the burden of ED can be comparable to chronic medical conditions like diabetes or heart disease. Anxiety about sexual performance and fear of failure exacerbates the problem, creating a cycle of performance anxiety. ED also profoundly affects intimate relationships, leading to communication difficulties and emotional distance between partners. Partners of men with ED may also experience reduced sexual satisfaction and relationship dissatisfaction. Men with ED often suffer from negative body image perceptions and diminished self-esteem due to their inability to achieve or maintain an erection, impacting their confidence and self-worth. Some men may even avoid intimate situations altogether to escape the fear of performance failure, further straining the relationship and reducing emotional closeness. ED can challenge a man's sense of sexual identity and masculinity, as they may question their sexual abilities and feel less desirable to their partners. Unfortunately, many men delay seeking treatment for ED due to embarrassment or shame associated with the condition. However, research indicates that seeking treatment for ED is associated with improved psychological well-being and quality of life.

Psychological interventions, such as cognitive-behavioral therapy and sex therapy, have proven effective in reducing psychological distress and improving sexual function and quality of life for men with ED. Involving partners in treatment and counseling positively impacts the psychological well-being of both men with ED and their partners. Couples therapy is beneficial in enhancing relationship satisfaction and intimacy, promoting healthier sexual and relational functioning. Erectile Dysfunction (ED) in men with diabetes is a complex condition with various interconnected mechanisms contributing to its development. High blood glucose levels play a central role, leading to endothelial dysfunction, nerve damage, hormonal imbalances, and psychological factors that collectively impact sexual function (Solomon *et al.*, 2003). Endothelial dysfunction results

from elevated glucose levels and involves oxidative stress, inflammation, and impaired nitric oxide synthesis, which ultimately compromise blood flow to the penile tissues. Additionally, nerve damage, particularly autonomic neuropathy, disrupts the necessary nerve signals required for achieving an erection. Hormonal imbalances, such as reduced testosterone levels, further contribute to ED by reducing sexual desire and impairing erectile function (Dwyera and Quinton, 2019). Psychological factors induced by hyperglycemia, including stress and anxiety, have a significant impact on sexual function, making it essential to address these aspects along with physiological factors to effectively manage and treat ED in diabetic men. A comprehensive approach encompassing medical management, lifestyle modifications, and psychological support is necessary for optimal outcomes in managing ED. Hyperglycemia-induced endothelial dysfunction involves the formation of advanced glycation end products (AGEs), leading to oxidative stress, inflammation, and the production of reactive oxygen species (ROS). Additionally, hyperglycemia disrupts nitric oxide synthesis and signaling, reducing NO bioavailability and impairing vasodilation. Activation of the polyol pathway and the release of pro-inflammatory cytokines further exacerbate endothelial dysfunction, ultimately leading to impaired blood flow to the penile tissues and contributing to ED. Hormonal imbalances in ED are influenced by hyperglycemia, leading to disruptions in hormone regulation, especially reduced testosterone levels. Insulin resistance, neural and synaptic damage, and the accumulation of AGEs further contribute to hormonal imbalances affecting sexual function. Dysregulation of growth hormone (GH) production and secretion, adrenal hormone imbalances, thyroid dysfunction, and disruptions in the hypothalamic-pituitary-gonadal (HPG) axis add complexity to the hormonal imbalances involved in ED. The psychological factors induced by hyperglycemia significantly impact ED. Stress, anxiety, depression, body image issues, strained relationships, and performance anxiety all contribute to sexual dysfunction. Chronic stress increases cortisol levels, affecting the release of sexual hormones and further exacerbating ED (Schmidt *et al.*, 2013). Addressing these psychological factors is crucial for effective management, involving therapy, counseling, stress reduction techniques, and diabetes education and support to improve overall well-being and alleviate ED. Plant-derived therapeutic agents show promise as potential treatments for ED due to their ability to improve sexual function and overall health. Plant-derived therapeutic agents like *Panax ginseng*, *Tribulus Terrestris*, Maca, Epimedium, Yohimbine, and Ginkgo biloba have been studied for

their effects on ED (Melnyk, and Marcone, 2011). These plant-based agents may enhance erectile function through various mechanisms, such as increasing nitric oxide production, enhancing penile blood flow, and promoting smooth muscle relaxation. Combining these plant-derived agents with conventional therapies may offer complementary approaches to optimize treatment outcomes.

*The Future Perspectives on Managing ED:* Future perspectives in managing ED hold exciting possibilities, such as gene therapy, stem cell therapy, and neural stimulation techniques. These innovative therapies may offer targeted and individualized treatments for ED by considering patient characteristics and underlying causes, potentially improving efficacy and reducing side effects. Nanotechnology advancements may also lead to more efficient drug delivery systems for ED medications, enhancing their targeted delivery and effectiveness. Emphasizing lifestyle modifications, collaborative care, and personalized medicine may provide comprehensive and tailored approaches to managing ED effectively.

Despite these promising advancements, managing ED presents several challenges. The psychological impact, underreporting, and stigma surrounding the condition hinder open discussions and timely medical help-seeking. The complex etiology of ED, involving multiple underlying causes, requires comprehensive evaluations to determine the exact cause in individual patients. Non-responsiveness to conventional therapies and lifestyle changes may pose challenges in finding alternative or combination treatments for non-responders. Comorbidities and medication side effects complicate management, necessitating careful consideration of treatment options. Limited access to specialized healthcare services in some regions may lead to suboptimal treatment and outcomes for ED.

In conclusion, ED in men with diabetes involves complex interactions of physiological and psychological factors. Addressing hyperglycemia-induced endothelial dysfunction, hormonal imbalances, and psychological factors is crucial for effective management. Plant-derived therapeutic agents and potential future therapies offer promising treatment options, but further research is needed to establish their efficacy and safety. Managing ED requires a comprehensive and individualized approach, considering patient characteristics, underlying causes, and lifestyle modifications to optimize treatment outcomes.

## REFERENCE

- Albersen, M; Shindel, AW; Lue, TF (2009). Sexual dysfunction in the older man. *Reviews in Clin Gerontol.* 19 (4), 237-248.
- Andersson, KE (2003). Erectile physiological and pathophysiological pathways involved in erectile dysfunction. *The J Urol .* 170(2), S6-S14.
- Avagianou, PA. (2014). Cognitive behavioral therapy in sexual dysfunction. In *Erectile dysfunction in hypertension and cardiovascular disease: A guide for clinicians* (pp. 205-211). Cham: Springer International Publishing.
- Baskerville, TA; Douglas, AJ. (2010). Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. , *CNS Neurosci Ther.* 16(3), e92-e123.
- Belew, D; Klaassen, Z; Lewis, RW. (2015). Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. *Sex Med Rev,* 3(1), 11-23.
- Bivalacqua, TJ; Liu, T; Musicki, B; Champion, HC; Burnett, AL. (2007). Endothelial nitric oxide synthase keeps erection regulatory function balanced in the penis. *Eur Urol,* 51(6), 1732-1740.
- Bivalacqua, TJ; Usta, MF; Champion, HC; Kadowitz, PJ; Hellstrom, WJ. (2003). Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. *J Androl ,* 24(S6), S17-S37.
- Byers, ES. (2005). Relationship satisfaction and sexual satisfaction: A longitudinal study of individuals in long-term relationships. *J Sex Res,* 42(2), 113-118.
- Camacho, ME; Reyes-Ortiz, CA. (2005). Sexual dysfunction in the elderly: age or disease? *Int J Impot Res.,* 17(1), S52-S56.
- Chen, KK; Chen, MT; Lo, KY; Chang, LS. (1996). Dynamic infusion cavernosometry and cavernosography (DICC) in the evaluation of vasculogenic impotence. *Zhonghua yi xue za zhi=; Chin Med J. Free China ed,* 57(4), 266-273.
- Cohen, J; Nassau, DE; Patel, P; Ramasamy, R. (2020). Low testosterone in adolescents & young adults. *Front Endocrinol ,* 10, 916
- Corona, G; Mannucci, E; Mansani, R; Petrone, L; Bartolini, M; Giommi, R; Maggi, M. (2004). Aging

- and pathogenesis of erectile dysfunction. *Int J Impot Res.* 16(5), 395-402.
- Davies, KP. (2015). Development and therapeutic applications of nitric oxide-releasing materials to treat erectile dysfunction. *Fut Sci. OA*, 1(1).
- Dwyer, AA; Quinton, R. (2019). Anatomy and physiology of the hypothalamic-pituitary-gonadal (HPG) axis. *Adv Pract Endocrinol Nurs.*, 839-852.
- El-Sakka, AI; Yassin, AA. (2010). Amelioration of penile fibrosis: myth or reality. *J Androl*, 31(4), 324-335
- Grover, S; Shouan, A. (2020). Assessment scales for sexual disorders—a review. *Journal of Psychosexual Health*, 2(2), 121-138.
- Guay, AT; Spark, RF; Bansal, S; Cunningham, GR; Goodman, NF; Nankin, HR; Mechanick, J. I. (2003). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem—2003 update. *Endocr Pract.* 9(1), 77-95.
- Gur, S; Abdel-Mageed, AB; Sikka, SC; Hellstrom, WJ. (2018). Advances in stem cell therapy for erectile dysfunction. *Expert Opin Biol Ther.*, 18(11), 1137-1150.
- Hatzimouratidis, K; Hatzichristou, D. (2007). Sexual dysfunctions: classifications and definitions. *J Sex Med*, 4(1), 241-250
- Jackson, G; Rosen, RC; Kloner, RA; Kostis, JB. (2006). The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. *J Sex Med*, 3(1), 28-36.
- Jiang, N.;Wu, C.; Zhou, X; Zhai, G; Wu, J. (2021). Cavernous nerve injury resulted in erectile dysfunction and regeneration. *J Immunol Res.*, 2021.
- Kloner, RA; Speakman, M. (2002). Erectile dysfunction and atherosclerosis. *Curr Atheroscler Rep.* 4(5), 397-401.
- Krzastek, SC; Bopp, J; Smith, RP; Kovac, JR. (2019). Recent advances in the understanding and management of erectile dysfunction. *F1000Research*, 8
- Laumann, EO; Nicolosi, A; Glasser, DB; Paik, A; Gungell, C; Moreira, E; Wang, T. (2005). Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors, *Int J Impot Res.*17(1), 39-57
- Leung, AC; Christ, GJ; Melman, A. (2004). Physiology of penile erection and pathophysiology of erectile dysfunction. *Atlas of Male Sexual Dysfunction*, 1-25.
- Lin, G; Reed-Maldonado, AB;Wang, B; Lee, YC; Zhou, J; Lu, Z; Lue, TF. (2017). In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy. *J Sex Med*, 14(4), 493-501.
- Ma, M; Yu, B; Qin, F; Yuan, J. (2020). Current approaches to the diagnosis of vascular erectile dysfunction. *Transl Androl Urol* 9(2), 709
- McCabe, MP; Sharlip, ID; Lewis, R; Atalla, E; Balon, R; Fisher, AD; Segraves, R. T. (2016). Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. *J Sex Med*, 13(2), 144-152.
- Melnyk, JP; Marcone, MF. (2011). Aphrodisiacs from plant and animal sources—A review of current scientific literature. *Food Res. Int* 44(4), 840-850.
- Montorsi, F; Salonia, A; Deho', F; Cestari, A; Guazzoni, G; Rigatti, P; Stief, C. (2003). Pharmacological management of erectile dysfunction. *BJU Int*, 91(5), 446-454.
- Müller, A; Mulhall, JP. (2006). Cardiovascular disease, metabolic syndrome, and erectile dysfunction. *Curr Opin Urol*, 16(6), 435-443.
- Nehra, A; Moreland, RB. (2001). Neurologic erectile dysfunction. *Urol Clin North Am.* 28(2), 289-308.
- Nguyen, HMT; Gabrielson, AT; Hellstrom, WJ (2017). Erectile dysfunction in young men—a review of the prevalence and risk factors. *Sex Med Rev* 5(4), 508-520.
- Rajfer, J. (2000). Relationship between testosterone and erectile dysfunction. *Rev Urol*, 2(2), 122.
- Rhoden, EL; Telöken, C; Sogari, PR; Vargas Souto, CA. (2002). The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. *Int J Impot Res*, 14(4), 245-250.



- Rosen, RC. (2001). Psychogenic erectile dysfunction: classification and management. *Urol Clin North Am.* 28(2), 269-278.
- Ryu, JK; Cho, KS; Kim, SJ; Oh, KJ; Kam, SC; Seo, KK; Kim, SW. (2013). Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction. *World J Mens Health*, 31(2), 83-102.
- Schmidt, FP; Basner, M; Kröger, G; Weck, S; Schnorbus, B; Muttray, A; Münzel, T. (2013). Effect of nighttime aircraft noise exposure on endothelial function and stress hormone release in healthy adults. *Eur Heart J*, 34(45), 3508-3514.
- Solomon, H; Man, JW; Jackson, G. (2003). Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. *Heart*, 89(3), 251-253.
- Somers, VK; White, DP; Amin, R; Abraham, WT; Costa, F; Culebras, A; Young, T. (2008). Sleep apnea and cardiovascular disease: An American heart association/American College of cardiology foundation scientific statement from the American heart association council for high blood pressure research professional education committee, council on clinical cardiology, stroke council, and Council on cardiovascular nursing in collaboration with the national heart, lung, and blood institute national center on sleep disorders research (national institutes of health). *Circulation*, 118(10), 1080-1111.
- Talas, F; Kalih, R; Miedaner, T; McDonald, BA. (2016). Genome-wide association study identifies novel candidate genes for aggressiveness, deoxynivalenol production, and azole sensitivity in natural field populations of *Fusarium graminearum*. *Mol. Plant Microbe Interact.*, 29(5), 417-430.
- Toda, N. (2012). Age-related changes in endothelial function and blood flow regulation. *Pharmacol. Ther*, 133(2), 159-176.
- Tuteja, N; Chandra, M; Tuteja, R; Misra, M. K. (2004). Nitric oxide is a unique bioactive signaling messenger in physiology and pathophysiology. *J. Biomed. Biotechnol.* 2004(4), 227-237.
- Valeiro, C; Matos, C; Scholl, J; van Hunsel, F. (2022). Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. *Drug Saf*, 45(6), 639-650.
- Wright, PJ. (2006). Comparison of phosphodiesterase type 5 (PDE5) inhibitors. *Int J Clin Pract.*, 60(8), 967-975.
- Wyllie, MG. (2005). The underlying pathophysiology and causes of erectile dysfunction. *Clin. Cornerstone*, 7(1), 19-26.
- Zhang, X; Sui, Z. (2013). Deciphering the selective androgen receptor modulators paradigm. *Expert Opin. Drug Discov*, 8(2), 191-218.